This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...
Active shortages reached 323 in Q1 2024, with persistent durations and major chemotherapy impact; the burden includes rationing, delayed/canceled care, and substantial hospital labor costs. Generic ...
Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply chain independence from China actually requires. As McHam notes, much of the ...
A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain ...
China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions. China's new pharmaceutical supply chain regulations have transformed a chronic ...
Market expansion is being fueled by high-cost specialty launches and persistent access friction, amid substantial adherence-related system costs and low first-year fill rates driven by payer ...
As health technology assessment (HTA) requirements evolve and joint clinical assessments (JCA) reshape Europe, pharma companies face growing pressure to align evidence, access, and strategy earlier in ...
Market growth is propelled by high-cost specialty therapies, payer friction, and complex access pathways, making hub and patient support infrastructure increasingly central to commercialization and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results